Who Optimizes SG&A Costs Better? Rhythm Pharmaceuticals, Inc. or ImmunityBio, Inc.

Biotech Giants: Who Masters SG&A Cost Efficiency?

__timestampImmunityBio, Inc.Rhythm Pharmaceuticals, Inc.
Wednesday, January 1, 201443260001213000
Thursday, January 1, 20152262060003425000
Friday, January 1, 2016943910006311000
Sunday, January 1, 2017538210009518000
Monday, January 1, 20183546300028080000
Tuesday, January 1, 20194645600036550000
Wednesday, January 1, 20207131800046125000
Friday, January 1, 202113525600068486000
Saturday, January 1, 202210270800092032000
Sunday, January 1, 2023129620000117532000
Loading chart...

Cracking the code

Optimizing SG&A Costs: A Tale of Two Biotechs

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, ImmunityBio, Inc. and Rhythm Pharmaceuticals, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, ImmunityBio's SG&A expenses fluctuated significantly, peaking in 2015 with a staggering 2.26 times more than their 2014 expenses. Meanwhile, Rhythm Pharmaceuticals showed a more consistent increase, with their SG&A costs rising nearly 97 times from 2014 to 2023. By 2023, Rhythm Pharmaceuticals had narrowed the gap, with their expenses reaching approximately 92% of ImmunityBio's. This trend suggests a strategic shift in Rhythm's cost management, potentially positioning them for greater financial efficiency. As these companies continue to innovate, their ability to control SG&A expenses will be pivotal in sustaining growth and competitiveness.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025